Daridorexant, a dual orexin receptor antagonist developed by Idorsia Pharmaceuticals, has undergone Phase 3 clinical trials for the treatment of insomnia [1]. These trials, known as theisticated Sleep and Wake research (iDreaMS) program, aimed to evaluate the efficacy and safety of daridorexant in adults with chronic insomnia disorder [2].
How effective is daridorexant in treating insomnia?
Phase 3 studies demonstrated that daridorexant significantly improved key insomnia endpoints. Patients treated with daridorexant showed improvements in sleep onset latency (time taken to fall asleep) and wake after sleep onset (time spent awake after initially falling asleep) compared to placebo [2][3]. Specifically, patients reported falling asleep faster and staying asleep longer [2].
What are the main findings from the Idorsia daridorexant Phase 3 trials?
The iDreaMS program included two pivotal Phase 3 studies. Both trials met their primary endpoints, showing statistically significant improvements in sleep onset and sleep maintenance in patients receiving daridorexant compared to placebo [2][4]. The studies also assessed subjective sleep quality and daytime functioning, with positive results reported for these measures as well [2].
What dosage of daridorexant was used in Phase 3 trials?
Phase 3 trials investigated two different doses of daridorexant: 25 mg and 50 mg [2]. Both dosages were found to be effective, although the specific outcomes for each dose are detailed in the trial publications [2][4].
When does the patent for daridorexant expire?
The patent landscape for daridorexant is complex, with multiple patents covering the drug. Information on patent expiry dates for specific daridorexant patents can be found on specialized pharmaceutical patent tracking websites [5].
What are the potential side effects of daridorexant?
Common side effects reported in Phase 3 trials included somnolence (drowsiness) and headache [3]. The studies also monitored for adverse events to establish the safety profile of daridorexant [2].
When was daridorexant approved by regulatory bodies?
Idorsia announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for daridorexant in January 2021 [6]. Regulatory decisions from agencies like the FDA and the European Medicines Agency (EMA) followed based on the submitted clinical data [7].
How does daridorexant work to treat insomnia?
Daridorexant is a dual orexin receptor antagonist. It works by blocking the binding of orexin neuropeptides to OX1R and OX2R receptors. Orexins are a key driver of wakefulness, and by inhibiting their action, daridorexant promotes sleep initiation and maintenance [1][8].
What is the difference between daridorexant and other insomnia medications?
Unlike some other insomnia medications that directly sedate the brain, daridorexant targets the wakefulness system [8]. This mechanism is intended to reduce the drive for wakefulness rather than inducing sleep through general central nervous system depression, potentially offering a different side effect profile [1][8].
Are there any ongoing studies or research for daridorexant?
Beyond the initial Phase 3 trials, Idorsia has conducted or is involved in further studies to explore daridorexant's long-term efficacy and safety, as well as its potential in different patient populations [2].
Sources:
[1] https://www.drugpatentwatch.com/drug/daridorexant
[2] https://www.businesswire.com/news/home/20210922005275/en/Idorsia-Announces-Positive-Top-Line-Results-from-the-Second-Phase-3-Study-of-Daridorexant-in-Adults-with-Insomnia
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa2114210
[4] https://www.idorsia.com/media/news-releases/2021/09/22/idorsia-announces-positive-top-line-results-from-the-second-phase-3-study-of-daridorexant-in-adults-with-insomnia
[5] https://www.drugpatentwatch.com/
[6] https://www.idorsia.com/media/news-releases/2021/01/27/idorsia-submits-new-drug-application-for-daridorexant-to-the-u.s.-food-and-drug-administration
[7] https://www.novartis.com/news/media-releases/novartis-and-idorsia-announce-novel-treatment-insomnia-receives-recommendation-europen-commission-marketing-authorization
[8] https://www.drugtargetreview.com/news/daridorexant-approved-treat-insomnia/